Global Rheumatic Disorders Drugs Market to 2024
Summary
The rheumatic
disorder therapy area is multi-disciplinary in nature and encompasses
conditions that affect joints, connective tissue, ligaments, tendons,
cartilage, bone and muscle and which are characterized by chronic pain and a
consequent reduction in function and motion. The majority of rheumatic
disorders are treated using largely genericized pain management drugs, and
there are no cures for any of the key indications, leaving a large unmet need
for better disease-modifying drugs to be developed.
This report covers
all rheumatic disorders, but there is a particular focus on five key diseases,
rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus
erythematosus and psoriatic arthritis, as these conditions have the largest
pipelines within the therapy area.
Scope
- How is the
rheumatic disorders landscape expected to change?
- Which drugs will
face patent expiry, biosimilar competition and decreasing revenue over the
forecast period?
- Overall, there
are 1,069 products in the rheumatic disorder pipeline, how does the composition
of the pipeline compare with that of the existing market?
- Which molecular
targets are most prominent within the pipeline and how do the key indications
differ in terms of their pipeline composition?
- The market size
for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in
2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will
contribute to market growth most, and which will achieve blockbuster status?
- What types of
companies are involved in the rheumatic disorder therapy area?
- Will the current
market leaders retain their dominance over the forecast period?
Reasons to buy
This report will
allow you to -
- Understand the
current clinical and commercial landscape by considering disease pathogenesis,
diagnosis, prognosis and the treatment options available at each stage of
diagnosis for the five key indications
- Identify trends
and developments in the rheumatic disorder pipeline and consider market
opportunities and potential risks by examining trends in clinical trial
duration and size, as well as clinical trial failure rates
- Identify which
two drug classes will see particularly strong market growth over the forecast
period
- Identify
commercial opportunities in the rheumatic disorder deal landscape by analyzing
trends in licensing and co-development deals
Get a free sample research report:
View Full
Report on Rheumatic Disorders Drugs Market
Contact Us
JSB Market Research
Phone: +917710006748
Comments
Post a Comment